Form 8-K

8-K — Spectral AI, Inc.

Accession: 0001213900-26-041479

Filed: 2026-04-08

Period: 2026-04-03

CIK: 0001833498

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0285483-8k_spectral.htm (Primary)

EX-99.1 — OFFER LETTER, BY AND BETWEEN DAVID MCGUIRE AND SPECTRAL AI, INC., DATED APRIL 3, 2026 (ea028548301ex99-1.htm)

EX-99.2 — PRESS RELEASE ISSUED BY SPECTRAL AI, INC. ON APRIL 8, 2026 (ea028548301ex99-2.htm)

GRAPHIC (ea028548301_ex99-1img1.jpg)

GRAPHIC (ea028548301_ex99-2img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0285483-8k_spectral.htm · Sequence: 1

false

0001833498

2026-04-03

0001833498

MDAI:CommonStockParValue0.0001PerShareMember

2026-04-03

0001833498

MDAI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf2.75PerShareMember

2026-04-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

April 3, 2026

SPECTRAL

AI, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40058

85-3987148

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

2515

McKinney Avenue, Suite

1000

Dallas,

Texas

75201

(Address of principal executive offices)

(Zip Code)

(972) 499-4934

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols

Name of each exchange on

which registered

Common Stock, par value $0.0001 per share

MDAI

The Nasdaq Stock Market LLC

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

MDAIW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of

Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

announced in the press release attached to this Current Report on Form 8-K, the Board of Directors (the “Board”) of the Spectral

AI, Inc. (the “Company”) have appointed David McGuire to the position of Chief Financial Officer beginning on May 4, 2026

(the “Effective Date”).

Mr. McGuire has over 20 years of experience in

finance and accounting, including significant experience in financial reporting, investor relations, financial planning and analysis,

capital markets activities, finance transformation, and tax matters. Prior to joining the Company, Mr. McGuire served as Chief Accounting

Officer of Solo Brands, Inc., a publicly traded company, where he was responsible for the company’s accounting, financial reporting,

internal control, and tax functions, including efforts related to material weakness remediation. Previously, Mr. McGuire served as Deputy

Chief Financial Officer and Chief Accounting Officer of EZCORP, Inc., a publicly traded provider of pawn transactions and consumer financial

services, where he was involved in financial reporting, investor relations, financial planning and analysis, capital markets activities,

merger and acquisition diligence and integration, and accounting operations. Earlier in his career, Mr. McGuire spent approximately 14

years with Ernst & Young LLP in its audit and financial accounting advisory practices, where he advised clients on complex accounting

matters, financial reporting and transactions. He also has experience advising companies on accounting and finance transformation initiatives.

Mr. McGuire holds a Bachelor of Business Administration

and a Masters in Professional Accounting from The University of Texas at Austin and is a Certified Public Accountant.

Mr. McGuire, age 47, will receive annual base

compensation of $330,000. He will be eligible for an annual target bonus of up to 30% of his annual base compensation, payable upon the

achievement of certain milestones and performance goals, as specified by the Board. He will be granted stock options under and subject

to the terms of the Company’s 2023 Long Term Incentive Plan on the date of employment, to acquire 150,000 shares of common stock

of the Company at an exercise price as of the Effective Date. The stock options will vest annually with the first installment vesting

on the first anniversary of the grant date and subsequent installments on each of the next two anniversary dates of the grant date thereafter,

as may be applicable. Upon a change of control of the Company, the stock options will become fully vested prior to the change of control.

A copy of Mr. McGuire’s employment agreement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01. Regulation FD Disclosure.

On April 8, 2026, the Company issued a press release

announcing the appointment of Mr. McGuire as Chief Financial Officer, a copy of which is furnished as Exhibit 99.2 to this Current Report

on Form 8-K.

The information in this Item 7.01 to this Current

Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed to be “filed” for purposes of Section

18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities

of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as

amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Offer Letter, by and between David McGuire and Spectral AI, Inc., dated April 3, 2026.

99.2

Press Release issued by Spectral AI, Inc. on April 8, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 8, 2026

SPECTRAL AI, INC.

By:

/s/ Vincent S. Capone

Name:

Vincent S. Capone

Title:

Chief Executive Officer

EX-99.1 — OFFER LETTER, BY AND BETWEEN DAVID MCGUIRE AND SPECTRAL AI, INC., DATED APRIL 3, 2026

EX-99.1

Filename: ea028548301ex99-1.htm · Sequence: 2

Exhibit 99.1

April 3, 2026

David McGuire

[…]

Re: Offer of Employment

Dear David,

Spectral AI, Inc. (the “Company”)

is pleased to make an offer of employment to you as the Chief Financial Officer of the Company, subject to the terms set forth in this

letter (the “Letter”), with an anticipated start date of May 4, 2026 (the “Start Date”), pending

a successful completion of a background check. The terms of your position with the Company are as set forth below.

1. POSITION. The Company will employ you

as its Chief Financial Officer, and you will report to Vincent Capone, Chief Executive Officer. You will be assigned various tasks and

responsibilities from time to time and your job is to fully and timely execute these responsibilities. You agree to the best of your ability

and experience that you will, at all times, loyally and conscientiously perform all of the duties and obligations required of and from

the Company. You will also be expected to comply with the Company’s policies and procedures which will be provided to you on the

Start Date.

2. COMPENSATION.

a. Salary. Your annual salary will be $330,000

(the “Annual Salary”), payable according to the normal business practices of the Company. Currently, payroll for employees

is paid on the 3rd and the 20th of each month.

b. Discretionary Bonus. You will be eligible

(but not guaranteed) to receive an annual discretionary bonus of up to thirty percent (30%) of your Annual Salary which, among other things,

will be based upon the achievement of certain metrics including (i) your perceived performance, (ii) your perceived contribution to the

revenue and profitability of the Company and (iii) other factors deemed relevant the Company, in each case, as written in the Employee

Bonus Policy. For the calendar year of 2026, you will be eligible to receive a minimum guaranteed bonus of $50,000 provided

your employment with the Company is not terminated for any reason or no reason whatsoever prior to reaching the six month anniversary

of your start date (“Anniversary Date”).

i. Sign-on Bonus. As

a special incentive, you shall receive a one-time bonus of $10,000 to be paid on the payroll date following your Start Date. In

the event your employment with the Company is terminated for any reason or no reason whatsoever prior to the Anniversary Date, you shall

be required to refund a pro-rated portion of the Sign-on Bonus equivalent to the time remaining between the date of termination and the

Anniversary Date, calculated on a daily basis.

c. Retirement Plan. Following your first

three (3) months of employment the Company will provide you with the opportunity to participate in the Company’s 401(k) Plan (the

“Plan”), where the Company will match your contributions dollar-for-dollar for up to 6% of your Annual Salary. The Company

reserves the right to terminate or amend the Plan from time to time in its discretion without liability to you.

Page 1

of 11

d. Option Grant. Subject to the approval

of the Board of Directors, you will be entitled to receive an option grant (the “Grant”) of an option to acquire up

to 150,000 common shares of Spectral AI), at an exercise price as of the Start Date which shall vest annually over a three-year period.

The Grant shall provide for the acceleration of vesting upon a Change of Control of the Company as more fully set forth in the Stock Option

Agreement. The Grant is subject to the terms of the Stock Option Agreement which you will execute in connection with the Grant and the

Company Option Plan, copies of which will be made available to you on your Start Date (the “Plan Documents”).

3. EMPLOYEE BENEFITS. The Company will

provide you with the opportunity to participate in the standard Company benefits plans currently available to other employees, subject

to any eligibility requirements imposed by such plans, to commence on the first of the month following the Start Date.

4. PAID TIME OFF (TIME BANK). Upon your

first day of employment, you will become eligible to participate in the Spectral AI Time Bank. You will accrue 10 hours a month to be

used in lieu of sick or vacation time. This is the equivalent of 15 days annually. In addition to your accrued time, you shall be entitled

to the company paid U.S. federal holidays. Only 120 hours of time off may be carried over each year.

5. CONFIDENTIAL INFORMATION AND OUTSIDE ACTIVITIES.

As a condition of your employment, you will execute the Confidentiality, Non-Compete and Proprietary Rights Agreement (the “CNC

Agreement”) attached to this Letter at Exhibit A and by signing this Letter, you affirm the terms and conditions

thereof.

6. NO CONFLICTING OBLIGATIONS. You understand

and agree that by signing this Letter, you represent to the Company that your performance will not breach any other agreement to which

you are a party, you have received any and all consents from third parties that may be required for the execution, delivery and performance

herewith and that you have not, and will not, during the term of your employment with the Company, enter into any oral or written agreement

in conflict with any of the provisions of this Letter or the Company’s policies. You are not to bring with you to the Company or

use or disclose to any person associated with the Company, any confidential or proprietary information belonging to any former employer

or other person or entity with respect to which you owe an obligation of confidentiality under any agreement or otherwise.

7. “AT-WILL” EMPLOYMENT. Employment

with the Company is for no specific period of time. Your employment with the Company is and will continue to be “at-will.”

This means that either you or the Company may terminate your employment relationship at any time, and for any reason or

no reason whatsoever. You will not be entitled to notice, payment or any other compensation upon your termination (other than the

compensation due to you for the period from your most recent paycheck through the date of termination and as otherwise expressly agreed

to herein). Whilst your job duties, title, compensation and benefits as well as the Company’s personnel policies and procedures

may change from time to time, the “at-will” nature of your employment cannot be changed or retracted, either orally or in

writing, or by any policy or conduct, except by an express written document stating that your employment is no longer at-will, which is

approved by the CEO.

8. ADDITIONAL INFORMATION. This Letter

(including the attached CNC Agreement) is the entire agreement between you and the Company. The Company reserves the right to modify or

amend the terms of your employment at any time for any reason and any such modification or amendments shall be by express written agreement

signed by you and the CEO. Any contrary representations, whether oral, written or implied, which have been made to you with respect to

the matters described in this Letter, are superseded by this Letter. This Letter will be governed by the laws of Texas, without regard

to conflict of laws principles and provisions.

Page 2

of 11

9. TERMINATION.

(a). If your is terminated

by the Company without Cause or by you with Good Reason, then, for a period of three (3) months following the effective date of termination,

you shall be entitled to (i) continue to receive your then-current Annual Salary; (ii) continue to participate in group medical and dental

plans for Company employees to the extent permitted under applicable law and, subject to any employee contribution applicable from time

to time, the Company shall continue to contribute to the premium cost of your participation in the Company’s group medical and dental

plans as set forth in this Agreement, provided that you are entitled to continue such participation under applicable law and plan terms;

and (iii) have all unvested stock options, stock grants and any other deferred compensation previously granted to you become fully vested.

In addition, the Company shall pay you any discretionary bonus that is accrued and unpaid. The Company’s obligation to provide you

a severance pay and benefits and the vesting of any unvested stock options, stock grants, and any other deferred compensation as may be

set forth above, is conditioned on You executing and delivering to the Company a release of claims acceptable to the Company and such

release not having been revoked or breached by you.

The then-current Annual Salary

to which you may become entitled under this Section 9(a) shall be payable in accordance with the normal payroll practices of the Company

and will begin at the Company’s next regular payroll period which is at least five business days following the later of the effective

date of the release of claims or the date the release is executed and delivered by you. You shall not be entitled to any other salary,

compensation or benefits after termination, except as specifically provided for in this Agreement, the Company’s employee benefit

plans or as otherwise expressly provided for in any other agreement between the parties or as required by applicable law.

For purposes of this Agreement,

“Final Compensation” means (i) any Base Salary earned but not paid during the final payroll period of your employment through

the date of termination, and (ii) any business expenses incurred by you but un-reimbursed on the date of termination, provided that such

expenses and required substantiation and documentation are submitted within fifteen (15) days of the date of termination and that such

expenses are reimbursable under Company policy.

(b). If your employment

terminates due to your death or Disability, in addition to the Final Compensation, the Company shall pay you (or, as applicable, your

estate) (i) any bonus compensation otherwise payable pursuant to Section 2 for the fiscal year preceding that in which termination occurs

that is unpaid on the date of termination; (ii) and all unvested stock options or other grants granted to you become vested. The Company’s

obligation to provide you with such payments and the vesting of any unvested stock options or other grants as set forth in the preceding

sentence, is conditioned on your or a duly authorized representative of your estate executing and delivering to the Company a release

of claims acceptable to the Company and such release becoming effective, and only so long as it has not revoked or breached the provisions

of the release or breached the provisions of any non-compete, non-disclosure obligations of you to the Company entered into at the time

of employment.

(c). If your employment

is terminated for any reason other than by the Company without Cause, by you for Good Reason, or due to your death or Disability, you

shall only be entitled to Final Compensation and shall not be entitled to any other salary, bonus, compensation or benefits thereafter,

except as otherwise specifically provided for under the Company’s employee benefit plans or as otherwise expressly required by applicable

law.

Page 3

of 11

(d). Except as otherwise

expressly provided herein, all of your rights to salary, bonuses, employee benefits and other compensation hereunder which would have

accrued or become payable after the termination or expiration of your employment shall cease upon such termination or expiration, other

than those expressly required under applicable law (such as COBRA). The Company may offset any amounts you may owe to the Company against

any amounts the Company owes you hereunder, subject to Section 409A of the Internal Revenue Code of 1986, as amended.

(e). For purposes of this

Agreement, “Cause” shall mean with respect to you one or more of the following: (i) willful failure to perform your duties

(other than any such failure resulting from illness, temporary absence, legal incapacity due to Disability), after reasonable written

notice of such failure and an opportunity to correct such failure within thirty (30) days, if correctable; (ii) willful failure to follow

reasonable and lawful directives of the CEO or Board of Directors, after reasonable notice of such failure and an opportunity to remedy

or cure such conduct within thirty (30) days, if curable; (iii) your conduct which the CEO or Board of Directors in its good faith discretion

determines would cause the Company or any of its subsidiaries substantial public disgrace or disrepute or substantial economic harm; (iv)

your conviction of an offense involving moral turpitude or any felony; (v) your breach of any material fiduciary duty with respect to

the Company which causes the Company demonstrable and material financial harm; (vi) your gross negligence or willful misconduct with respect

to the Company resulting in material and demonstrable financeable harm to the Company; or (vii) your material breach of this Agreement,

after reasonable notice of such breach and an opportunity to cure such breach within ten (10) business days, if curable. No event or conduct

shall constitute Cause for termination unless the Company exercises its right to terminate your employment within 60 days of the discovery

by the Company of the occurrence of the underlying event constituting Cause.

(f). For purposes of this

Agreement, “Disability” shall mean your inability to perform the essential duties, responsibilities and functions of your

position with the Company for a period of 90 consecutive days or for a total of 120 days during any 12-month period as a result of any

mental or physical illness, disability or incapacity even with reasonable accommodations for such illness, disability or incapacity provided

by the Company or if providing such accommodations would be unreasonable, all as determined by the Board of Directors in its reasonable

good faith judgment. If any question shall arise as to whether during any period you are disabled through any illness, injury, accident

or condition of either a physical or psychological nature so as to be unable to perform substantially all of your duties and responsibilities

hereunder, you may, and at the request of the Company shall, submit to a medical examination by a physician selected by the Company to

whom you have no reasonable objection to determine whether you are so disabled and such determination shall for the purposes of this Agreement

be conclusive of the issue. If such a question arise and you shall fail to submit to such medical examination, the Company’s determination

of the issue shall be binding on you.

(g). For the purposes of

this Agreement, “Good Reason” shall mean the occurrence of one or more of the following without your written consent: (i)

the Company reduces the amount of the Base Salary, excluding an identical percentage reduction of the Base Salary conducted as part of

a similar reduction applicable to all officers of the Company, (ii) the Company changes your primary place of work to a location that

is more than seventy-five (75) miles from your present primary place of work, (iii) the Company changes your title or otherwise reduces

your responsibilities in a manner which is materially inconsistent with the positions you hold (including, without limitation, a change

in reporting structure such that you no longer report to the CEO), or (iv) the Company materially breaches this Agreement; provided, however,

that no event described in clause (i), (ii), (iii), or (iv) will constitute Good Reason unless (X) Youhas given the Company written notice

of the Good Reason objection, setting forth the conduct of the Company that is alleged to constitute Good Reason, within thirty (30) days

after the occurrence of such conduct, (Y) you have provided the Company with thirty (30) days following the date on which such notice

is provided to cure such conduct, and the Company has failed to do so, and (Z) You have provided notice of resignation within fourteen

(14) days of the lapse of the cure period. Failing such cure, a termination of employment by you for Good Reason would be effective on

the date the Company receives the notice of resignation.

Page 4

of 11

This offer is confidential and can only be disclosed

to your immediate family and to your legal and financial advisers. If the offer terms are acceptable to you – after reading this

Letter, carefully considering the terms, and, if needed, discussing these terms with your legal and financial advisers – please

sign in the space below and return a copy to the Company. This Letter will then govern the relationship between you and the Company.

Sincerely,

/s/ Vincent S. Capone

Vincent S. Capone

Chief Executive Officer

Spectral AI, Inc.

I, David McGuire, accept the offer on the terms

and conditions outlined above.

Date

April 3, 2026

/s/ David McGuire

Employee Signature

Page 5

of 11

Exhibit A

CONFIDENTIALITY, NON-COMPETE AND PROPRIETARY RIGHTS

AGREEMENT

1. My obligations under this Confidentiality, Non-Compete and Proprietary Rights Agreement (hereafter in

this Exhibit A, “Agreement”) are to the Company and its subsidiaries, affiliates, and successors, as

such may be from time to time, including a company that in the event of a merger and acquisition (“M&A”) buys the

Company’s operations and/or activities in whole or in part (the “Company’s Affiliates”).

2. Confidentiality: I will regard and retain as strictly confidential and will not, directly or indirectly,

disclose to any third party, or use for any unauthorized purposes either during or at any time after the term of my employment with the

Company without limitation regarding time or place, any Confidential Information (as defined below) that I have acquired during my employment

or in consequence of my employment or association with the Company or the Company’s Affiliates, without the written consent of an

authorized representative of the Company.

“Confidential Information.”

As used herein, “Confidential Information” means all Company information or data disclosed orally, in writing or in electronic

format, at any time, and whether or not marked as “confidential” or “proprietary,” which is not generally available

to the public, including, but not limited to, the Company’s actual or anticipated business or research and development, technical

data, trade secrets or know-how, product plans or other information regarding the Company’s and/or the Company’s Affiliates’

products or services and markets therefor, customer lists and customers, software, developments, inventions, processes, formulas, technology,

designs, drawings, engineering, hardware configuration information, marketing, finance, methods of manufacture, other business information,

or other non-public information that a competitor of the Company or a Company Affiliate could use to the competitive disadvantage of the

Company or a Company Affiliate. However, Confidential Information shall not include such information or data that:

a. I can demonstrate was already lawfully in my possession prior to the time of disclosure;

b. Is publicly available or later becomes generally available to the public other than

as a result of disclosure by me or any other party owing a confidentiality or similar obligation to the Company or a Company Affiliate;

c. Becomes available to me on a non-confidential basis from any third-party not owing

a confidentiality or similar obligation to the Company or a Company Affiliate;

d. Is independently developed by me without access to the Company’s Confidential

Information; or

Page 6

of 11

e. Is information I disclose pursuant to judicial, regulatory, or statutory mandate,

provided I (i) give the Company prompt written notice of such legal requirement so that the Company has the opportunity to pursue its

rights regarding such potential disclosure and (ii) utilize reasonable efforts to obtain reliable assurances that the person receiving

the Confidential Information will maintain the confidentiality of the same.

I acknowledge that all such Confidential

Information is essential commercial and proprietary information of the Company and/or the Company’s Affiliates, or third parties

to whom the Company or the Company’s Affiliates owe a duty of confidentiality, is not public information and cannot easily be discovered

by others. The confidentiality of the Confidential Information provides the Company and/or the Company’s Affiliates a commercial

advantage over its competitors, and the Company is taking reasonable measures to safeguard its confidentiality.

3. Return of Confidential Information: All Confidential Information, whether contained in documents,

electronic media, magnetic media, servers or otherwise (collectively, the “Documents”), including, but not limited

to, notebooks, notes, memoranda, records, diagrams, blueprints, bulletins, formulas, reports, computer programs, other data of any kind

coming into my possession or prepared by me or others, are the exclusive property of the Company and/or of the Company’s Affiliates,

as the case may be. I agree to return to the Company or, if return is not feasible, destroy all such Documents immediately upon the earlier

of: (i) a demand from the Company; or (ii) termination of my employment with the Company. I agree to certify the destruction of all such

Documents, in writing, to the Company within ten (10) calendar days of such demand or such termination from employment.

4. Rights in Inventions: I hereby acknowledge and will in the future acknowledge the Company’s

(including, as applicable, the Company’s Affiliates) sole and exclusive right, title, and interest, domestic and foreign, in and

to all Inventions (as defined below). Accordingly, without additional compensation, all right, title and interest of every kind and nature

whatsoever in and to all Inventions I solely or jointly conceive and/or reduce to practice throughout the world while employed or working

in collaboration with the Company, including all rights of priority under International Conventions, are hereby assigned to the Company

(including, as applicable, the Company’s Affiliates), and shall be the sole and exclusive property of Company for any purposes or

uses whatsoever. All costs and expenses associated with establishing the Company’s rights therein shall be the Company’s responsibility.

I hereby agree to assist the Company in any reasonable manner to obtain and enforce for the Company’s benefit any patents or other

property rights in any and all countries, with respect to any Inventions, and I agree to execute, when requested, declarations, oaths,

or statements of use for patent, copyright, trademark, or similar applications and assignments to Company and any other lawful documents

deemed necessary by Company to carry out the purposes of this Agreement with respect thereto. In the event that Company is unable for

any reason to secure my signature on any document required to apply for or execute any patent, copyright or other application with respect

to any Inventions (including improvements, renewals, extensions, continuations, divisions or continuations in part thereof), after a written

demand is made therefore upon me, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my

agents and attorneys-in-fact to act for and on my behalf and instead of myself, to execute and file any such application and to do all

other lawfully permitted acts to further the prosecution and issuance of patents, copyrights, mask works or other rights thereon with

the same legal force and effect as if executed by myself.

Page 7

of 11

5. Without derogating from the aforementioned and in as much as such rights cannot be assigned or transferred

to the Company, I hereby explicitly waive (i) any interest, claim or demand that I have, or may have in the future for, or may be entitled

to, with respect to consideration, compensation or royalty payment in connection with the Inventions, including, but not limited to, any

claims for consideration, compensation or royalty payments pursuant to any applicable law; (ii) any moral rights, artists’ rights,

or any other similar rights worldwide (“Moral Rights”) that I had, have or may have in the future in or with respect

to the Inventions. I hereby acknowledge and declare that the monthly salary and other monetary benefits provided under the terms of the

Letter to which this Agreement is attached constitute the entire compensation to which I am entitled and include any and all consideration

with respect to Inventions which I have developed, made, authored, contributed to or worked on, in whole or in part, independently or

jointly with others. I hereby waive all claims and agree never to assert against the Company and/or the Company’s Affiliates or

licensees, any (i) rights to receive consideration, compensation or royalty payment in connection with the Inventions and/or (ii) Moral

Rights.

“Inventions” herein

means, collectively, all inventions, ideas, improvements, mask works, data, discoveries, works, designs, know-how, original works of authorship,

formulae, concepts, techniques, methods, systems, processes, compositions of matter, computer software programs, databases, and trade

secrets, whether or not capable of being patented or copyrighted or protectable as trade secrets, including improvements and derivatives

thereof, which during my employment with the Company or six (6) months thereafter (or a lesser maximum period permitted by law), I may

conceive, reduce to practice, make, develop, author, or work on, in whole or in part, independently or jointly with others and:

a. which are related to the Company’s Business (as defined below); or

b. which are related to the Company’s actual or demonstrably anticipated research

and development, or to any of the Company’s Affiliates’ actual or demonstrably anticipated research and development which

relates to the Company’s Business (as defined below); and

c. which are developed in whole or in part on the Company’s time or with the

use of any of the Company’s or any of the Company’s Affiliates’ equipment, supplies, facilities, or Confidential Information.

Page 8

of 11

The Company’s “Business,”

as used in this Agreement refers to any business activity of the Company as currently conducted and as currently proposed to be conducted,

including without limitation, related to medical imaging device research, development, manufacturing, and/or sale.

6. Disclosure and Assignment of Inventions: I will promptly disclose, reduce to writing, and describe

to the Company or to the Company’s Affiliates (as determined at the sole and absolute discretion of the Company) all Inventions.

Immediately upon the request of the Company or its Affiliates and/or as required under applicable law, I will promptly execute and sign

any written document required to effectuate, evidence and/or register the assignment to the Company or its designee(s) of all my rights,

title and interests with respect to any and all Inventions, pursuant to Sections 4 and 5 above.

7. Employee Assistance: I will, at the Company’s expense, assist in preparation and registration

of patents and all other intellectual property in favor of the Company or its designee(s) in any jurisdiction deemed appropriate by the

Company. Such assistance shall include, without limitation, the preparation of documents, drawings and other data and execution of assignments,

applications and other forms. I agree to perform this obligation during and after my employment with the Company.

8. Non-Competition: I agree that as long as I am in the employ of the Company and for a period of

one (1) year after termination of employment for any reason, I will not, directly or indirectly, either alone or jointly with others,

or as an employee, agent, consultant owner, partner, joint venturer, stockholder, broker, principal, corporate officer, director, licensor

or in any other capacity or as an employee of any person, firm or company, anywhere within a 100 mile radius of the Company’s principal

office, engage in, become financially interested in, be employed by or have any connection with any business or venture that is engaged

in any activities involving (i) products or services directly competing with the Company’s products or services, or with such of

the Company’s Affiliates products and services which relate to the Company’s Business, as they shall be at the time of termination

of my employment, or, (ii) information, processes, technology or equipment which directly competes with information, processes, technology

or equipment in which the Company has a proprietary interest, or in which any of the Company’s Affiliates then has a proprietary

interest and which are related to the Company’s Business. The foregoing shall not apply to (i) holdings of securities of any company

the shares of which are publicly traded on an internationally recognized stock exchange, which do not exceed 1% of the issued share capital

of such public company, so long as I have no active role in such public company as a director, officer, employee, consultant (including

as an independent consultant) or otherwise, or, (ii) de minimis non-commercial activities.

I further agree that as long as I am

in the employment of the Company and for a period of six (6) months after termination of employment, for any reason, I shall not directly,

either alone or jointly with others or as an employee, agent, consultant owner, partner, joint venturer, stockholder, broker, principal,

corporate officer, director, licensor or in any other capacity or as an employee of any person, firm or company, solicit, canvas or approach

in competition with the Company, any person or entity which, to my knowledge, was provided with goods or services by the Company (“Customer”)

or provided goods or services to the Company (“Provider”) at any time during the 12 months immediately prior to termination

of employment, for the purpose of offering or receiving goods or services of the same type as or similar to the goods or services supplied

or received by the Company on the termination date.

Page 9

of 11

9. Non-Solicitation: During the term of my service with the Company and for a period of one (1) year

after termination of employment for any reason, I will not, directly, including personally or in any business in which I am an employee,

officer, director, shareholder, consultant or contractor, for any purpose or in any place, solicit or encourage or endeavor to solicit

or encourage or cause others to solicit or encourage any employees of the Company or of the Company’s Affiliates to terminate their

employment with the Company or with the Company’s Affiliates as applicable.

10. No Conflicting Obligations: I will not disclose to the Company any confidential information or

material belonging to a third party, including any prior employer or contractor, unless I have first received the written approval of

that third party and present it to the Company.

11. Breach of Obligations: I am aware that a breach of my obligations as detailed above, or part of

them, may cause the Company or the Company’s Affiliates serious and irreparable damage, and that financial compensation may not

be an appropriate remedy to such damage. Therefore, I agree, that if such a breach occurs, the Company, any of the Company’s Affiliates

or any of their designee(s) shall be entitled, without prejudice, to take all legal means necessary, and seek all and any injunctive relief

as is necessary to restrain any continuing or further breach of this Agreement. I agree that the prevailing party in any action to enforce

this Agreement shall be entitled to full recovery of its attorneys’ fees.

12. Acknowledgements and Declarations:

I hereby declare and acknowledge

as follows:

a. My confidentiality and non-competition obligations under this Agreement are fair,

reasonable, and proportional, and are designed to protect the Company’s and the Company Affiliates’ secrets and their confidential

information, which constitute the essence of their protected business and commercial advantage in which significant capital investments

were made.

b. Any breach of my obligations under this Agreement shall contradict the nature of

the special trust and loyalty between me and the Company, the fair and proper business practices and the duty of good faith and fairness

between the parties. Any such breach shall harm the Company and/or the Company Affiliates and shall constitute a material breach of this

Agreement and the employment agreement to which this Agreement is attached.

Page 10

of 11

c. My obligations under this Agreement and the restricted period of time and geographical

area specified herein are reasonable and proportional, and do not prevent me from developing my general knowledge and professional expertise

in the area of my business, without infringing on or breaching any of the Company’s rights.

13. Assignment: The undertakings set forth herein may be assigned by the Company. I may not assign

or delegate my duties under this Agreement without the Company’s prior written approval. This Agreement shall be binding upon my

heirs, successors and permitted assignees.

14. Waiver. No failures or delay by the Company in exercising any right, power, or privilege hereunder

shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the

exercise of any right, power, or privilege hereunder.

15. Survival: If any one or more of the terms contained in this Agreement shall for any reason in any

judicial proceeding to be excessively broad with regard to time, geographic scope or activity, the term shall be construed in a manner

to enable it to be enforced to the extent compatible with applicable law.

ACKNOWLEDGED AND AGREED BY:

David McGuire

/s/ David McGuire

4/3/2026

Employee

Signature

Date

Page 11

of 11

EX-99.2 — PRESS RELEASE ISSUED BY SPECTRAL AI, INC. ON APRIL 8, 2026

EX-99.2

Filename: ea028548301ex99-2.htm · Sequence: 3

Exhibit 99.2

Spectral AI Names David McGuire, CPA, as Chief

Financial Officer

DALLAS, TX –

April 8, 2026 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence

(AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment

of David McGuire as the Company’s Chief Financial Officer, effective May 4, 2026.

“David’s

appointment as CFO is another important step in strengthening Spectral AI’s financial leadership and strategic readiness as we prepare

for commercialization of the DeepView® System,” said Vincent S. Capone, Spectral AI’s Chief Executive Officer. “David

is a seasoned public company executive with experience in global markets, finance, financial planning and analysis and internal controls,

and we are excited to welcome him to our team. His appointment underscores our commitment to strong financial governance.”

Mr. McGuire brings to

Spectral AI more than 20 years of experience in finance and accounting, including Sarbanes-Oxley 404 and financial reporting, investor

relations, financial planning and analysis, capital markets activities, finance transformation, and tax matters, with a track record of

scaling finance organizations and enhancing financial infrastructure in growing companies. Prior to joining Spectral AI, he served as

the Chief Accounting Officer of Solo Brands, Inc., a publicly-traded consumer products company, where he was responsible for overseeing

the accounting, financial reporting, internal controls, and tax functions, while also supporting broader finance and operational initiatives

to scale its public company infrastructure.

He also served as Deputy

Chief Financial Officer and Chief Accounting Officer of EZCORP, Inc., a multi-national, publicly-traded provider of consumer retail transactions

and consumer financial services, where he was responsible for financial operations and played a key role in capital markets activities

and broader strategic initiatives.

Mr. McGuire also served

as Managing Director at a professional services company where he built the firm’s Texas practice and advised growing companies on

finance and accounting transformation.

Mr. McGuire began his

career at Ernst & Young LLP, where he assumed positions of increasing responsibility over a 14-year career. He holds a Bachelor of

Business Administration and a Master in Professional Accounting from The University of Texas at Austin and is a Certified Public Accountant.

“I am honored and excited to assume the

role of CFO at this pivotal time in the Company’s history,” said Mr. McGuire. “I look forward to collaborating with

a talented team to advance our strategic priorities and enhance long-term shareholder value.”

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive

AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving

patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with

its DeepView System. The DeepView System is being developed as a predictive diagnostic device to offer clinicians an objective and immediate

assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and

a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment

insight towards value care by improving patient outcomes and reducing healthcare costs. Spectral AI has been named to TIME’s list

of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.

Forward-Looking Statements

Certain statements made in this release are “forward

looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation

Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook.

When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,”

“forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,”

“should,” “future,” “propose” and variations of these words or similar expressions (or the negative

versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees

of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important

factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those

discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing

factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with

the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company.

These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially

from those contained in the forward-looking statements.

Investors:

The Equity Group

Devin Sullivan

Conor Rodriguez

Managing Director

Associate

dsullivan@theequitygroup.com

crodriguez@theequitygroup.com

GRAPHIC

Filename: ea028548301_ex99-1img1.jpg · Sequence: 4

Binary file (8645 bytes)

Download ea028548301_ex99-1img1.jpg

GRAPHIC

Filename: ea028548301_ex99-2img1.jpg · Sequence: 5

Binary file (12499 bytes)

Download ea028548301_ex99-2img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Apr. 03, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 03, 2026

Entity File Number

001-40058

Entity Registrant Name

SPECTRAL

AI, INC.

Entity Central Index Key

0001833498

Entity Tax Identification Number

85-3987148

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2515

McKinney Avenue

Entity Address, Address Line Two

Suite

1000

Entity Address, City or Town

Dallas

Entity Address, State or Province

Entity Address, Postal Zip Code

75201

City Area Code

972

Local Phone Number

499-4934

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

MDAI

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

Title of 12(b) Security

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

Trading Symbol

MDAIW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=MDAI_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=MDAI_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf2.75PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: